Worldwide Wilsons Disease Industrial and Market studies: Industry Analysis & Outlook (2016-2020)
"Global
Wilsons Disease Market: Industry Analysis & Outlook (2016-2020)"
The Report covers current Market Trends, Analysis, Forecast, Review,
Share, Size, Growth, Effect.
Description-
Wilson’s
disease is a rare disease and is named after Kinnear Wilson who was
the first to describe this disorder in 1912. His description terms
the disease as a “progressive lenticular degeneration,” a
hereditary, fatal neurological disease that is usually accompanied by
chronic liver ailment that leads to a condition called cirrhosis.
Wilson's disease is a hereditary disorder that leads to unwarranted
accumulation of copper in crucial organs such as the liver, brain
etc. The patient starts to accumulate copper from birth but diagnosis
tends not to occur only in the later ages. The primary signs of
Wilson’s disease become prominent usually between the ages of 12
and 23 years.
Wilson’s
disease is caused by the mutation of a gene named ATP7B. Absent or
reduced function of ATP7B protein leads to reduced elimination of
copper into the bile. Wilson’s disease is inherited as an autosomal
recessive trait, which means that in order to develop the disease one
must inherit two procreations of the defective gene, one from each
parent. If a person receives only one abnormal gene from either of
the parents, he/she is not likely to get affected by the Wilson’s
disease. Wilson’s disease may be difficult to primarily diagnose as
the symptoms are alike to other health issues like heavy metal
poisoning, hepatitis C, and cerebral palsy.
The
important factors that are anticipated to drive the market include
rising prices of chelators in the US, rising attractiveness of orphan
drugs market, increasing global healthcare expenditure as well as
spending on medicines. The noteworthy trends in the market include
falling number of prescriptions for Wilson’s disease, and the
development of gene therapy as a potential cure for the disease.
However, the market is confronted by crucial challenges such as
under-diagnosis of the disease, lack of safety in treatments, poor
compliance to current treatments and unmet efficacy needs.
Table
of Content
1. Market Overview
1.1 Introduction
1.2 Causes
1.3 Symptoms
1.3.1 Hepatic Symptoms
1.3.2 Neurological Symptoms
1.3.3 Ophthalmic Symptoms
1.3.4 Other Symptoms
1.4 Diagnosis
1.5 Treatment through Medications
1.5.1 D-penicillamine
1.5.2 Trientine
1.5.3 Zinc Salts
1.5.4 Ammonium tetrathiomolybdate
1.5.5 Bis-Choline Tetrathiomolybdate – Decuprate
1.1 Introduction
1.2 Causes
1.3 Symptoms
1.3.1 Hepatic Symptoms
1.3.2 Neurological Symptoms
1.3.3 Ophthalmic Symptoms
1.3.4 Other Symptoms
1.4 Diagnosis
1.5 Treatment through Medications
1.5.1 D-penicillamine
1.5.2 Trientine
1.5.3 Zinc Salts
1.5.4 Ammonium tetrathiomolybdate
1.5.5 Bis-Choline Tetrathiomolybdate – Decuprate
2. Global Market
2.1 Global Orphan Drugs Market Revenue – Actuals
2.2 Global Orphan Drugs Market Revenue – Forecast
2.3 Wilson’s Disease Prevalence by Region
2.4 Wilson’s Disease Market by Treatment – New Patients
2.5 Wilson’s Disease Market by Treatment – Experienced Patients
2.6 Global Decuprate Revenue – Forecast
2.7 Global Liver Transplantation by Region
2.1 Global Orphan Drugs Market Revenue – Actuals
2.2 Global Orphan Drugs Market Revenue – Forecast
2.3 Wilson’s Disease Prevalence by Region
2.4 Wilson’s Disease Market by Treatment – New Patients
2.5 Wilson’s Disease Market by Treatment – Experienced Patients
2.6 Global Decuprate Revenue – Forecast
2.7 Global Liver Transplantation by Region
3. Regional Markets
3.1 Europe
3.1.1 Wilson’s Disease Prevalence – Forecast
3.1.2 Wilson’s Disease Market by Treatment
3.1.3 Wilson’s Disease Patients Treated with Zinc – Forecast
3.1.4 Wilson’s Disease Patients Treated with Chelators – Forecast
3.1.5 Wilson’s Disease Patients Treated with Decuprate – Forecast
3.2 The US
3.2.1 Wilson’s Disease Prevalence – Forecast
3.2.2 Wilson’s Disease Market by Treatment
3.2.3 Wilson’s Disease Patients Treated with Zinc – Forecast
3.2.4 Wilson’s Disease Patients Treated with Chelators – Forecast
3.2.5 Chelators Market Revenue – Actuals
3.2.6 Chelators Market Revenue – Forecast
3.1 Europe
3.1.1 Wilson’s Disease Prevalence – Forecast
3.1.2 Wilson’s Disease Market by Treatment
3.1.3 Wilson’s Disease Patients Treated with Zinc – Forecast
3.1.4 Wilson’s Disease Patients Treated with Chelators – Forecast
3.1.5 Wilson’s Disease Patients Treated with Decuprate – Forecast
3.2 The US
3.2.1 Wilson’s Disease Prevalence – Forecast
3.2.2 Wilson’s Disease Market by Treatment
3.2.3 Wilson’s Disease Patients Treated with Zinc – Forecast
3.2.4 Wilson’s Disease Patients Treated with Chelators – Forecast
3.2.5 Chelators Market Revenue – Actuals
3.2.6 Chelators Market Revenue – Forecast
Comments
Post a Comment